JP2017507163A - がん幹細胞の根絶または増殖阻害のための化合物 - Google Patents

がん幹細胞の根絶または増殖阻害のための化合物 Download PDF

Info

Publication number
JP2017507163A
JP2017507163A JP2016556295A JP2016556295A JP2017507163A JP 2017507163 A JP2017507163 A JP 2017507163A JP 2016556295 A JP2016556295 A JP 2016556295A JP 2016556295 A JP2016556295 A JP 2016556295A JP 2017507163 A JP2017507163 A JP 2017507163A
Authority
JP
Japan
Prior art keywords
compound
cancer
pharmaceutically acceptable
cancer stem
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016556295A
Other languages
English (en)
Japanese (ja)
Inventor
サンギータ スリヴァスタヴァ
サンギータ スリヴァスタヴァ
マイティリ アタヴァレ
マイティリ アタヴァレ
ケダール シュクレ
ケダール シュクレ
ガヤトリ モレ
ガヤトリ モレ
Original Assignee
ゴーダーヴァリ バイオリファイナリーズ リミテッド
ゴーダーヴァリ バイオリファイナリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゴーダーヴァリ バイオリファイナリーズ リミテッド, ゴーダーヴァリ バイオリファイナリーズ リミテッド filed Critical ゴーダーヴァリ バイオリファイナリーズ リミテッド
Publication of JP2017507163A publication Critical patent/JP2017507163A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2016556295A 2014-03-11 2015-03-11 がん幹細胞の根絶または増殖阻害のための化合物 Pending JP2017507163A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN814/MUM/2014 2014-03-11
PCT/IN2015/050019 WO2015136556A2 (en) 2014-03-11 2015-03-11 Compounds for eradicating or inhibiting proliferation of cancer stem cells
IN814MU2014 IN2014MU00814A (enExample) 2014-03-11 2015-03-11

Publications (1)

Publication Number Publication Date
JP2017507163A true JP2017507163A (ja) 2017-03-16

Family

ID=54072549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016556295A Pending JP2017507163A (ja) 2014-03-11 2015-03-11 がん幹細胞の根絶または増殖阻害のための化合物

Country Status (9)

Country Link
US (1) US20170022215A1 (enExample)
EP (1) EP3116882A4 (enExample)
JP (1) JP2017507163A (enExample)
AU (1) AU2015228385A1 (enExample)
CA (1) CA2940807A1 (enExample)
IL (1) IL247720A0 (enExample)
IN (1) IN2014MU00814A (enExample)
MX (1) MX2016011730A (enExample)
WO (1) WO2015136556A2 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD248593A1 (de) * 1985-01-11 1987-08-12 Univ Halle Wittenberg Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern
NZ546044A (en) * 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation

Also Published As

Publication number Publication date
IN2014MU00814A (enExample) 2015-09-25
CA2940807A1 (en) 2015-09-17
WO2015136556A3 (en) 2016-01-14
WO2015136556A2 (en) 2015-09-17
EP3116882A4 (en) 2017-08-02
MX2016011730A (es) 2016-12-14
EP3116882A2 (en) 2017-01-18
US20170022215A1 (en) 2017-01-26
AU2015228385A1 (en) 2016-09-15
IL247720A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
KR102633530B1 (ko) 혈액 장애를 치료하기 위한 화합물 및 조성물
CA2530884C (en) Trp-p8 active compounds and therapeutic treatment methods
CN107531683B (zh) Usp7抑制剂化合物及使用方法
CN113811333A (zh) 靶向抗癌核激素受体的化合物
US11932650B2 (en) Potent agelastatin derivatives as modulators for cancer invasion and metastasis
JP2019511553A (ja) 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ
JP2021500335A (ja) グルタミナーゼ阻害薬療法
BR112012033425A2 (pt) pirazoloquinolinas
US20160228399A1 (en) Pharmaceutical combinations for the treatment of cancer
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
US9867807B2 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
US20200246285A1 (en) Small molecule inhibitors of slc25a1
CN109942630A (zh) 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途
JP2017507163A (ja) がん幹細胞の根絶または増殖阻害のための化合物
CN112513000A (zh) 新型联苯衍生物化合物及其用途
CN105142643A (zh) 药物化合物
CN112999236B (zh) 乌本苷用于治疗脑干胶质瘤的用途
CN118845726B (zh) 环泊酚在治疗结直肠癌中的应用
US20250228950A1 (en) Prodrugs Activated by Reduction in the Cytosol
US20180169100A1 (en) Cancer Stem Cell Targeting Compounds
CN108299390A (zh) 抗肿瘤化合物dcz0415及其制备方法和应用
EP3720437A1 (en) Prodrugs activated by reduction in the cytosol